UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK

Diabetic medicine, 2013-06, Vol.30 (6), p.681-686

2013

Volltextzugriff (PDF)

Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes

Diabetes, obesity & metabolism, 2015-02, Vol.17 (2), p.170-178

2015

Volltextzugriff (PDF)

Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes

Diabetes, obesity & metabolism, 2015-01, Vol.17 (1), p.15-22

2015

Volltextzugriff (PDF)

O26 Les patients diabétiques de type 2 (DT2) avec un bon contrôle glycémique sous insuline ont moins d’événements cardiovasculaires et de mortalité: résultats de l’étude CREDIT

Diabetes & metabolism, 2015-03, Vol.41, p.A8-A8

2015

Volltextzugriff (PDF)

Continuation versus discontinuation of insulin secretagogues when initiating insulin in type 2 diabetes

Diabetes, obesity & metabolism, 2010-10, Vol.12 (10), p.923-925

2010

Volltextzugriff (PDF)

Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study

Diabetes, obesity & metabolism, 2009-04, Vol.11 (4), p.379-386

2009

Volltextzugriff (PDF)

Physical characteristics that predict final basal insulin dose in type 2 diabetes mellitus, with a special focus on BMI

Nutrition, metabolism, and cardiovascular diseases, 2014-12, Vol.24 (12), p.1354-1359

2014

Volltextzugriff (PDF)

A comparison of duration of first prescribed insulin therapy in uncontrolled type 2 diabetes

Diabetes research and clinical practice, 2011-12, Vol.94 (3), p.442-448

2011

Volltextzugriff (PDF)

Monitoring individual response to hormone replacement therapy with bone markers

Bone (New York, N.Y.), 2000-06, Vol.26 (6), p.553-560

2000

Volltextzugriff (PDF)

Matrix delivery transdermal 17β-estradiol for the prevention of bone loss in postmenopausal women

Osteoporosis international, 1999-04, Vol.9 (4), p.358-366

1999

Volltextzugriff (PDF)

Two-year glycaemic control and healthcare expenditures following initiation of insulin glargine versus neutral protamine Hagedorn insulin in type 2 diabetes

Diabetes, obesity & metabolism, 2011-08, Vol.13 (8), p.711-717

2011

Volltextzugriff (PDF)

A dose-ranging trial of a matrix transdermal 17β-estradiol for the prevention of bone loss in early postmenopausal women

Bone (New York, N.Y.), 1999-05, Vol.24 (5), p.517-523

1999

Volltextzugriff (PDF)

Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause

American journal of obstetrics and gynecology, 2000-01, Vol.182 (1), p.7-12

2000

Volltextzugriff (PDF)

Three-year follow-up of the use of transdermal 17β-estradiol matrix patches for the prevention of bone loss in early postmenopausal women

American journal of obstetrics and gynecology, 2001-01, Vol.184 (2), p.32-40

2001

Volltextzugriff (PDF)

Efficacy and tolerability of Menorest ® 50 compared with estraderm ® TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study

Maturitas, 1995-11, Vol.22 (3), p.207-218

1995

Volltextzugriff (PDF)

A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause

Obstetrics and gynecology (New York. 1953), 1999-10, Vol.94 (4), p.498-503

Archer, D

1999

Volltextzugriff (PDF)

Efficacy and tolerance of Menorest ® compared to Premarin ® in the treatment of postmenopausal women. A randomised, multicentre, double-blind, double-dummy study

Maturitas, 1995-09, Vol.22 (2), p.105-114

1995

Volltextzugriff (PDF)

Bioavailability Study of Menorest®, a New Estrogen Transdermal Delivery System, Compared with a Transdermal Reservoir System

Clinical drug investigation, 1995-09, Vol.10 (3), p.172-178

1995

Volltextzugriff (PDF)

Effects of transdermal hrt on vasomotor symptoms using either a sequential regimen or a continuous combined regimen

International journal of gynecology and obstetrics, 2000, Vol.70 (S3), p.C55-C56

2000

Volltextzugriff (PDF)

P3.13.04 Effect of transdermal estradiol/norethisterone HRT vs. estradiol on quality of life in postmenopausal women

International journal of gynecology and obstetrics, 2000, Vol.70 (S3), p.C119-C119

2000

Volltextzugriff (PDF)

Studies on the safety of treatment with transdermal patches containing estradiol and norethisterone (Estalis®)

International journal of gynecology and obstetrics, 2000, Vol.70 (S4), p.D138-D138

2000

Volltextzugriff (PDF)

Efficacy and Safety of Menorest (50 Mikrog/Day) Compared to Premarin 0.625 Mg in the Treatment of Menopausal Symptoms and the Prevention of Bone Loss, in Menopausal Women: A Single-center, Comparative, Randomized, Double-blind, Double-dummy Study

Scandinavian journal of rheumatology, 1996, Vol.25 (S103), p.89-90

1996

Volltextzugriff (PDF)

Clinical Evaluation of a New Triphasic Oral Contraceptive: Norgestimate and Ethinyl Estradiol

Acta obstetricia et gynecologica Scandinavica, 1992-01, Vol.71 (S156), p.27-32

1992

Volltextzugriff (PDF)

A Double-Blind, Double-Dummy, Comparative Study of Menorest 50® versus Premarin® 0.625mg in the Treatment of Menopausal Symptoms and the Prevention of Bone Loss in Patients with Menopausal Symptoms

Clinical drug investigation, 1996-04, Vol.11 (4), p.205-213

1996

Volltextzugriff (PDF)

A Comparison Study of Lipid and Androgen Metabolism with Triphasic Oral Contraceptive Formulations Containing Norgestimate or Levonorgestrel

Acta obstetricia et gynecologica Scandinavica, 1992-01, Vol.71 (S156), p.33-38

1992

Volltextzugriff (PDF)

1 – 25 von 161

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(137)
Mit Volltextzugriff
(135)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK

Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes

Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes

O26 Les patients diabétiques de type 2 (DT2) avec un bon contrôle glycémique sous insuline ont moins d’événements cardiovasculaires et de mortalité: résultats de l’étude CREDIT

Continuation versus discontinuation of insulin secretagogues when initiating insulin in type 2 diabetes

Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study

Physical characteristics that predict final basal insulin dose in type 2 diabetes mellitus, with a special focus on BMI

A comparison of duration of first prescribed insulin therapy in uncontrolled type 2 diabetes

Monitoring individual response to hormone replacement therapy with bone markers

Matrix delivery transdermal 17β-estradiol for the prevention of bone loss in postmenopausal women

Two-year glycaemic control and healthcare expenditures following initiation of insulin glargine versus neutral protamine Hagedorn insulin in type 2 diabetes

A dose-ranging trial of a matrix transdermal 17β-estradiol for the prevention of bone loss in early postmenopausal women

Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause

Three-year follow-up of the use of transdermal 17β-estradiol matrix patches for the prevention of bone loss in early postmenopausal women

Efficacy and tolerability of Menorest ® 50 compared with estraderm ® TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study

A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause

Efficacy and tolerance of Menorest ® compared to Premarin ® in the treatment of postmenopausal women. A randomised, multicentre, double-blind, double-dummy study

Bioavailability Study of Menorest®, a New Estrogen Transdermal Delivery System, Compared with a Transdermal Reservoir System

Effects of transdermal hrt on vasomotor symptoms using either a sequential regimen or a continuous combined regimen

P3.13.04 Effect of transdermal estradiol/norethisterone HRT vs. estradiol on quality of life in postmenopausal women

Studies on the safety of treatment with transdermal patches containing estradiol and norethisterone (Estalis®)

Efficacy and Safety of Menorest (50 Mikrog/Day) Compared to Premarin 0.625 Mg in the Treatment of Menopausal Symptoms and the Prevention of Bone Loss, in Menopausal Women: A Single-center, Comparative, Randomized, Double-blind, Double-dummy Study

Clinical Evaluation of a New Triphasic Oral Contraceptive: Norgestimate and Ethinyl Estradiol

A Double-Blind, Double-Dummy, Comparative Study of Menorest 50® versus Premarin® 0.625mg in the Treatment of Menopausal Symptoms and the Prevention of Bone Loss in Patients with Menopausal Symptoms

A Comparison Study of Lipid and Androgen Metabolism with Triphasic Oral Contraceptive Formulations Containing Norgestimate or Levonorgestrel

Suchergebnisse filtern